Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051516 · ClinicalTrials.gov registry record · Phase 4
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
A Phase 4 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 188
- Enrollment target
NCT03051516 is a Phase 4 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 188 participants.
The verdict
NCT03051516, a Phase 4 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 188 participants
- Enrollment target
Study Summary
This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill tumor cells and decrease the chance of vulvar or anal lesions to progress or come back.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- BIOLOGICAL Recombinant Human Papillomavirus Nonavalent Vaccine
- OTHER Placebo Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03051516
The ClinicalTrials.gov registry entry for NCT03051516 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03051516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03051516 about?
NCT03051516 is a clinical study titled "HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions". This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill tumor cells and decrease the ...
What is the current status of trial NCT03051516?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 188 participants. The study started on 2017-08-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03051516?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Recombinant Human Papillomavirus Nonavalent Vaccine (BIOLOGICAL), Placebo Administration (OTHER).
Who is sponsoring clinical trial NCT03051516?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.